Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840232 | 0.84 | ELANE (0.39) | ELANEL3MBTL1 | |
| SCHEMBL5041462 | 0.82 | ELANE (0.38) | ELANE | |
| SCHEMBL5744048 | 0.81 | ELANE (0.37) | ELANE | |
| SCHEMBL6672735 | 0.81 | ELANE (0.37) | ELANE | |
| SCHEMBL4972816 | 0.81 | ELANE (0.32) | ELANE | |
| SCHEMBL4972810 | 0.81 | ELANE (0.32) | ELANE | |
| SCHEMBL4733704 | 0.79 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL6656037 | 0.79 | CYP3A4 (0.36) | L3MBTL1 | |
| SCHEMBL5745833 | 0.79 | CYP3A4 (0.36) | L3MBTL1 | |
| SCHEMBL5569177 | 0.77 | ELANE (0.39) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414821-B1 | TRICYCLIC EPOXIDES | ALTANA PHARMA AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-6927292-B2 | Tricyclic epoxides | ALTANA PHARMA AG (DE) | 2005-08-09 | — | — | US | disclosed |
| US-20040235882-A1 | Amino-substituted imidazopyridines for the treatment of gastrointestial diseases | ALTANA PHARMA AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040235883-A1 | Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040176597-A1 | Tricyclic epoxides | ALTANA PHARMA AG (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-1419156-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA Pharma AG (DE) | 2004-05-19 | — | — | EP | disclosed |
| EP-1417208-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA Pharma AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1414821-A1 | TRICYCLIC EPOXIDES | ALTANA Pharma AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003016310-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003014120-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003014119-A1 | TRICYCLIC EPOXIDES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235883-A1 | Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders | SLC10A2, ALPI, SI | ELANE 1466/4885L3MBTL1 3637/4885 |
| US-20040235882-A1 | Amino-substituted imidazopyridines for the treatment of gastrointestial diseases | SLC10A2, ALPI, FABP6 | ELANE 754/4885L3MBTL1 3188/4885 |
| US-20040176597-A1 | Tricyclic epoxides | VKORC1, CYP2E1, CYP1A2 | ELANE 327/4885L3MBTL1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.